An Ethical Analysis of Medication Treatment for Opioid use Disorder (MOUD) for Persons who are Incarcerated

Abstract

Opioid use disorder (OUD) is highly prevalent among persons who are incarcerated. Medication treatment for opioid use disorder (MOUD), methadone, buprenorphine, and naltrexone, is widely used to treat OUD in the community. Despite MOUD's well-documented effectiveness in improving health and social outcomes, its use in American jails and prisons is limited.

Several factors are used to justify limited access to MOUD in jails and prisons including: “uncertainty” of MOUD's effectiveness during incarceration, security concerns, risk of overdose from MOUD, lack of resources and institutional infrastructure, and the inability of people with OUD to provide informed consent. Stigma regarding MOUD also likely plays a role. While these factors are relevant to the creation and implementation of addiction treatment policies in incarcerated settings, their ethicality remains underexplored.

Using ethical principles of beneficence/non-maleficence, justice, and autonomy, in addition to public health ethics, we evaluate the ethicality of the above list of factors. There is a two-fold ethical imperative to provide MOUD in jails and prisons. Firstly, persons who are incarcerated have the right to evidence-based medical care for OUD. Secondly, because jails and prisons are government institutions, they have an obligation to provide that evidence-based treatment. Additionally, jails and prisons must address the systematic barriers that prevent them from fulfilling that responsibility. According to widely accepted ethical principles, strong evidence supporting the health benefits of MOUD cannot be subordinated to stigma or inaccurate assessments of security, cost, and feasibility. We conclude that making MOUD inaccessible in jails and prisons is ethically impermissible.

Keywords

Opioids corrections ethics medication treatment for opioid use disorder

Get full access to this article

View all access options for this article.

References

Boutwell

, Nijhawan

, Zaller

, Rich

. Arrested on heroin: a national opportunity. J Opioid Manage 2007;3(6):328–332.

Winkelman

TNA

, Chang

, Binswanger

. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558.

Lopez

. How America's prisons are fueling the opioid epidemic. Vox Media. https://www.vox.com/policy-and-politics/2018/3/13/17020002/prison-opioid-epidemic-medications-addiction. Published 2018. Accessed September 22, 2019.

WHO Model List of Essential Medicines. https://www.who.int/medicines/publications/essentialmedicinesEML_2015_FINAL_amended_NOV2015.pdf. Published 2015. Accessed September 22, 2019.

Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. World Health Organization https://www.who.int/substance_abuse/publications/opioid_dependence_guidelines.pdf. Published 2009. Accessed September 22, 2019.

Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document. HHS Publication No. (SMA) 19-5063FULLDOC. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.

Moore

, Roberts

, Reid

, Smith

KMZ

, Oberleitner

LMS

, McKee

. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review. J Subst Abuse Treat. 2019;99:32–43.

Hedrich

, Alves

, Farrell

, Stöver

, Møller

, Mayet

. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction. 2012;107(3):501–517.

Vestal

. New Momentum for Addiction Treatment Behind Bars. The Pew Chartiable Trusts. https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2018/04/04/new-momentum-for-addiction-treatment-behind-bars. Published 2018. Accessed May 19, 2019.

10.

Linden

, Marullo

, Bone

, Barry

, Bell

. Prisoners as patients: the opioid epidemic, medication-assisted treatment, and the eighth amendment. J Law Med Ethics. 2018;46(2):252–267.

11.

Backus

. Funding to help CT prisons improve opioid addiction treatment program. The Middletown Press. https://www.middletownpress.com/middletown/article/Funding-to-help-CT-prisons-improve-opioid-14069347.php. Published 2019. Accessed September 19, 2019.

12.

Faher

. More than 500 Vermon inmates recieving addiction treatment VTDigger. https://vtdigger.org/2019/01/23/500-vermont-inmates-receiving-addiction-treatment/. Published 2019. Accessed September 19, 2019.

13.

Vestal

. At Rikers Island, a Legacy of Medication-Assisted Opioid Treatment. The Pew Charitable Trusts. https://www.pewtrusts.org/en/researchandanalysis/blogs/stateline/2016/05/23/at-rikers-island-a-legacy-of-medicationassisted-opioid-treatment. Published 2016. Accessed September 19, 2019.

14.

Jones

. New York State Must Take Action to Reduce Opioid Overuse Deaths. Vera Institute of Justice. Think Justic Blog Web site. https://www.vera.org/blog/new-york-statemust-take-action-to-reduce-opioid-overuse-deaths. Published 2019. Accessed September 19, 2019.

15.

Governor Baker Signs Second Major Piece of Legislation to Address Opioid Epidemic in Massachusetts. Commonwealth of Massachusets. https://www.mass.gov/news/governor-baker-signs-second-major-piece-of-legislation-to-address-opioid-epidemic-in. Published 2018. Accessed October 6, 2019.

16.

Governor Murphy Announces New Initiatives to Combat the Opioid Epidemic. State of New Jersey. https://www.nj.gov/governor/news/news/562019/approved/20190123b.shtml. Published 2019. Accessed October 6, 2019.

17.

Friederich

. Corrections Takes Steps to Help Curb State's Opioid Epidemic. Washington State Department of Corrections. https://www.doc.wa.gov/news/2018/11132018.htm. Published 2018. Accessed May 19, 2019.

18.

Nunn

, Zaller

, Dickman

, Trimbur

, Nijhawan

, Rich

. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1–2):83–88.

19.

McKenzie

, Nunn

, Zaller

, Bazazi

, Rich

. Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. J Opioid Manage 2009;5(4):219–227.

20.

Public Policy Statement: Definition of Addiction American Soceity of Addiction Medicine. https://www.asam.org/docs/default-source/public-policystatements/1definition_of_addiction_long_4-11.pdf?sfvrsn=a8f64512_4. Published 2011. Accessed September 21, 2019.

21.

Leshner

, Dzau

. Medication-based treatment to address opioid use disorder. JAMA 2019;321(21):2071–2072.

22.

Wakeman

, Rich

. Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018;53(2):330–333.

23.

McMillan

, Lapham

. Staff perspectives on methadone maintenance therapy (MMT) in a large southwestern jail. Addict Res Theor. 2005;13(1):53–63.

24.

Link

, Phelan

. Conceptualizing stigma. Annu Rev Sociol. 2001;27(1):363–385.

25.

Krieger

. Embodying inequality: a review of concepts, measures, and methods for studying health consequences of discrimination. Int J Health Serv. 1999;29(2):295–352.

26.

Ahern

, Stuber

, Galea

. Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depend. 2007;88(2–3):188–196.

27.

Olsen

, Sharfstein

. Confronting the stigma of opioid use disorder–and its treatment. JAMA 2014;311(14):1393–1394.

28.

Friedmann

, Hoskinson

, Gordon

. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abuse 2012;33(1):9–18.

29.

Matusow

, Dickman

, Rich

, . Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44(5):473–480.

30.

Rich

, Boutwell

, Shield

, . Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005;82(3):411–419.

31.

White

, Ali

, Larance

, Zador

, Mattick

, Degenhardt

. The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film. Drug Alcohol Rev. 2016;35(1):76–82.

32.

Goodnough

, Zezima

. When Children's Scribbles Hide a Prison Drug. The New York Times. https://www.nytimes.com/2011/05/27/us/27smuggle.html. Published 2011. Accessed September 27, 2019.

33.

Faul

, Bohm

, Alexander

. Methadone prescribing and overdose and the association with medicaid preferred drug list policies - United States, 2007–2014. MMWR Morb Mortal Wkly Rep. 2017;66(12):320–323.

34.

Lofwall MR , Walsh

. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8(5):315–326.

35.

Coll

. The jail health-care crisis. Conde Nast. https://www.newyorker.com/magazine/2019/03/04/the-jail-health-care-crisis. Published 2019. Accessed 09/22, 2019.

36.

Henrichson

, Delaney

. The price of prisons: what incarceration costs taxpayers. Fed Sentencing Rep 2012;25:68.

37.

Caplan

. Ethical issues surrounding forced, mandated, or coerced treatment. J Subst Abuse Treat. 2006;31(2):117–120.

38.

Cohen

. Untreated addiction imposes an ethical bar to recruiting addicts for non‐therapeutic studies of addictive drugs. J Law Med Ethics. 2002;30(1):73–81.

39.

Elliott

. Who holds the leash? Am J Bioeth. 2002;2(2):48–48.

40.

Charland

. Cynthia's dilemma: consenting to heroin prescription. Am J Bioeth. 2002;2(2):37–47.

41.

Ludwig

, Peters

. Medication-assisted treatment for opioid use disorders in correctional settings: an ethics review. Int J Drug Pol. 2014;25(6):1041–1046.

42.

Moser

, Arndt

, Kanz

, . Coercion and informed consent in research involving prisoners. Compr Psychiatry. 2004;45(1):1–9.

43.

Gostin

. Biomedical research involving prisoners ethical values and legal regulation. JAMA 2007;297(7):737–740.

44.

Beauchamp

TLC

, James

. Principles of Biomedical Ethics. New York: Oxford University Press; 2009.

45.

U.S. Department of Health and Human Services (HHS), Office of the Surgeon General. Facing addiction in America: the surgeon general's spotlight on opioids. https://addiction.surgeongeneral.gov/sites/default/files/Spotlight-on-Opioids_09192018.pdf. Published 2018. Accessed September 22, 2019.

46.

American Correctional Association and American Society of Addiction Medicine Release Joint Policy Statement on Opioid Use Disorder Treatment in the Justice System. American Correctional Association. https://www.aca.org/ACA_Prod_IMIS/DOCS/ACA-ASAM Press Release and Joint Policy Statement 3.20.18.pdf. Published 2019. Accessed September 23, 2019.

47.

Mattick

, Breen

, Kimber

, Davoli

. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003;(2):CD002209.

48.

Mattick

, Breen

, Kimber

, Davoli

. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004;(3):CD002207.

49.

Marsden

, Stillwell

, Jones

, . Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Addiction 2017;112(8):1408–1418.

50.

Niveau

. Relevance and limits of the principle of “equivalence of care” in prison medicine. J Med Ethics. 2007;33(10):610–613.

51.

Magura

, Lee

, Hershberger

, . Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend. 2009;99(1–3):222–230.

52.

National Institute on Drug Abuse. Treating Opioid Addiction in Criminal Justice Settings National Institute on Drug Abuse. https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/policybrief-cj.pdf. Published 2017. Accessed September 21, 2019.

53.

Jones

. Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths—United States, 2002–2014. MMWR Morb Mortal Wkly Rep. 2016;6526:667–671.

54.

Cicero

, Ellis

, Chilcoat

. Understanding the use of diverted buprenorphine. Drug Alcohol Depend. 2018;193:117–123.

55.

Pilkinton

, Pilkinton

. Prescribing in prison: minimizing psychotropic drug diversion in correctional practice. J Correct Health Care. 2014;20(2):95–104.

56.

Farahmand

, Modesto-Lowe

, Chaplin

. Prescribing opioid replacement therapy in US correctional settings. J Am Acad Psychiatry Law 2017;45(4):472–477.

57.

Kuehn

. Methadone overdose deaths rise with increased prescribing for pain. JAMA 2012;308(8):749–750.

58.

Modesto-Lowe

, Brooks

, Petry

. Methadone deaths: risk factors in pain and addicted populations. J Gen Intern Med. 2010;25(4):305–309.

59.

Estelle v. Gamble, 429 U.S. 97 (1976). Justia. https://supreme.justia.com/cases/federal/us/429/97/#tab-opinion-1952035. Accessed October 22, 2019.

60.

Rold

. Thirty years after Estelle v. Gamble: a legal retrospective. J Correct Health Care. 2008;14(1):11–20.

61.

Assembly UG. United Nations standard minimum rules for the treatment of prisoners (the Nelson Mandela Rules). UN GA Res 2015;70:175.

62.

Carter

, Hall

. Informed consent to opioid agonist maintenance treatment: recommended ethical guidelines. Int J Drug Pol. 2008;19(1):79–89.

63.

Jeste

, Saks

. Decisional capacity in mental illness and substance use disorders: empirical database and policy implications. Behav Sci Law 2006;24(4):607–628.

64.

Bonnie

. Judicially mandated naltrexone use by criminal offenders: a legal analysis. J Subst Abuse Treat. 2006;31(2):121–127.

65.

Childress

, Faden

, Gaare

, . Public health ethics: mapping the terrain. J Law Med Ethics. 2002;30(2):170–178.

66.

Hughes

, James Wilson

. Reentry Trends in the United States. Bureau of Justice Statistics. https://www.bjs.gov/content/reentry/reentry.cfm. Published 2019. Accessed September 27, 2019.

67.

Why does heroin use create special risk for contracting HIV/AIDS and hepatitis B and C? National Institute on Drug Abuse. https://www.drugabuse.gov/publications/research-reports/heroin/why-are-heroin-users-special-risk-contracting-hivaids-hepatitis-b-c. Published 2018. Accessed September 2, 2019.

68.

National Institute on Drug Abuse. Principles of drug abuse treatment for criminal justice populations – a research-based guide. National Institute of Drug Abuse. https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/txcriminaljustice_0.pdf. Published 2014. Accessed September 23, 2019.

69.

Larney

. Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. Addiction. 2010;105(2):216–223.

70.

Murphy

, Polsky

. Economic evaluations of opioid use disorder interventions. Pharmacoeconomics 2016;34(9):863–887.